|
1
|
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
|
J Clin Oncol
|
2005
|
8.08
|
|
2
|
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
|
J Clin Oncol
|
2006
|
6.95
|
|
3
|
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
|
JAMA
|
2010
|
4.71
|
|
4
|
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
|
J Clin Oncol
|
2006
|
4.27
|
|
5
|
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
|
Cancer Res
|
2010
|
3.24
|
|
6
|
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
|
J Clin Oncol
|
2009
|
2.94
|
|
7
|
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.
|
JAMA
|
2007
|
2.84
|
|
8
|
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.
|
J Clin Oncol
|
2011
|
2.76
|
|
9
|
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803.
|
J Clin Oncol
|
2008
|
2.74
|
|
10
|
Comparative genomic analysis of primary versus metastatic colorectal carcinomas.
|
J Clin Oncol
|
2012
|
2.74
|
|
11
|
Association of family history with cancer recurrence and survival among patients with stage III colon cancer.
|
JAMA
|
2008
|
2.67
|
|
12
|
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment.
|
J Clin Oncol
|
2009
|
2.50
|
|
13
|
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
|
Clin Cancer Res
|
2011
|
2.40
|
|
14
|
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.
|
Clin Cancer Res
|
2009
|
2.02
|
|
15
|
Potential regional differences for the tolerability profiles of fluoropyrimidines.
|
J Clin Oncol
|
2008
|
1.92
|
|
16
|
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
|
J Clin Oncol
|
2005
|
1.82
|
|
17
|
Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors.
|
J Clin Oncol
|
2002
|
1.78
|
|
18
|
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.
|
Genome Biol
|
2014
|
1.76
|
|
19
|
The camptothecins.
|
Lancet
|
2003
|
1.68
|
|
20
|
Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients.
|
J Am Coll Surg
|
2002
|
1.65
|
|
21
|
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
|
J Clin Oncol
|
2013
|
1.62
|
|
22
|
Individualized prediction of colon cancer recurrence using a nomogram.
|
J Clin Oncol
|
2008
|
1.61
|
|
23
|
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
|
J Clin Oncol
|
2014
|
1.59
|
|
24
|
Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy.
|
Ann Surg
|
2012
|
1.58
|
|
25
|
Evolving treatment of advanced colon cancer.
|
Annu Rev Med
|
2009
|
1.56
|
|
26
|
Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?
|
Am J Surg Pathol
|
2008
|
1.54
|
|
27
|
Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation.
|
Cancer
|
2008
|
1.53
|
|
28
|
Bevacizumab 5 mg/kg can be infused safely over 10 minutes.
|
J Clin Oncol
|
2007
|
1.52
|
|
29
|
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease.
|
Ann Surg Oncol
|
2002
|
1.50
|
|
30
|
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.
|
Invest New Drugs
|
2007
|
1.47
|
|
31
|
Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors.
|
Oncology
|
2011
|
1.44
|
|
32
|
Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.
|
J Cancer Res Clin Oncol
|
2009
|
1.38
|
|
33
|
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
|
J Clin Oncol
|
2010
|
1.38
|
|
34
|
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.
|
Cancer
|
2014
|
1.32
|
|
35
|
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.
|
J Clin Oncol
|
2011
|
1.31
|
|
36
|
Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
|
J Clin Oncol
|
2010
|
1.24
|
|
37
|
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2009
|
1.24
|
|
38
|
Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
|
J Natl Cancer Inst
|
2012
|
1.20
|
|
39
|
Role of expression profiling in carcinoma of unknown primary remains unknown.
|
J Clin Oncol
|
2013
|
1.20
|
|
40
|
Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature.
|
Hum Pathol
|
2012
|
1.20
|
|
41
|
Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy.
|
Clin Cancer Res
|
2005
|
1.15
|
|
42
|
Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803.
|
Cancer
|
2010
|
1.14
|
|
43
|
A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.
|
Cancer
|
2012
|
1.13
|
|
44
|
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
|
J Natl Cancer Inst
|
2011
|
1.12
|
|
45
|
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.
|
N Engl J Med
|
2014
|
1.07
|
|
46
|
Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.
|
J Natl Cancer Inst
|
2011
|
1.06
|
|
47
|
Adjuvant therapy of colon cancer: current status and future directions.
|
Cancer J
|
2007
|
1.06
|
|
48
|
Current management of advanced hepatocellular carcinoma.
|
Gastrointest Cancer Res
|
2008
|
1.04
|
|
49
|
Palliative care in the outpatient oncology setting: evaluation of a practical set of referral criteria.
|
J Oncol Pract
|
2011
|
1.04
|
|
50
|
Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer.
|
J Natl Compr Canc Netw
|
2014
|
1.01
|
|
51
|
Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis.
|
Radiother Oncol
|
2013
|
1.00
|
|
52
|
Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.99
|
|
53
|
Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome.
|
Ann Surg Oncol
|
2012
|
0.99
|
|
54
|
Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision.
|
Ann Surg Oncol
|
2011
|
0.98
|
|
55
|
Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
|
Ann Surg Oncol
|
2006
|
0.98
|
|
56
|
Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis.
|
Ann Surg Oncol
|
2011
|
0.97
|
|
57
|
Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study.
|
Ann Surg
|
2013
|
0.97
|
|
58
|
Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors.
|
Nat Clin Pract Oncol
|
2009
|
0.96
|
|
59
|
KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice.
|
Oncologist
|
2011
|
0.96
|
|
60
|
Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa.
|
Cancer
|
2006
|
0.92
|
|
61
|
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
|
J Natl Cancer Inst
|
2013
|
0.92
|
|
62
|
p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.
|
Clin Cancer Res
|
2009
|
0.90
|
|
63
|
Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803.
|
J Clin Oncol
|
2010
|
0.89
|
|
64
|
Biomarkers in colorectal cancer: added value or just added expense?
|
Expert Rev Mol Diagn
|
2008
|
0.87
|
|
65
|
Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism?
|
J Clin Oncol
|
2010
|
0.87
|
|
66
|
Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.
|
Clin Cancer Res
|
2013
|
0.86
|
|
67
|
Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.86
|
|
68
|
Antibody-based therapies for colorectal cancer.
|
Oncologist
|
2005
|
0.85
|
|
69
|
Serum 25-hydroxy vitamin D and survival in advanced colorectal cancer: a retrospective analysis.
|
Nutr Cancer
|
2015
|
0.84
|
|
70
|
Doxorubicin and sorafenib for treatment of advanced hepatocellular cancer.
|
Gastroenterology
|
2011
|
0.83
|
|
71
|
FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation.
|
Dis Colon Rectum
|
2012
|
0.82
|
|
72
|
Irinotecan (Campto) in the treatment of pancreatic cancer.
|
Expert Rev Anticancer Ther
|
2003
|
0.82
|
|
73
|
Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer.
|
Cancer
|
2012
|
0.80
|
|
74
|
First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents.
|
Clin Colorectal Cancer
|
2008
|
0.79
|
|
75
|
Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer.
|
Clin Colorectal Cancer
|
2013
|
0.78
|
|
76
|
Surgery and high-dose-rate intraoperative radiation therapy for recurrent squamous-cell carcinoma of the anal canal.
|
Dis Colon Rectum
|
2011
|
0.78
|
|
77
|
Biologic agents in the treatment of colorectal cancer: the last decade; the lost decade?
|
Am Soc Clin Oncol Educ Book
|
2013
|
0.77
|
|
78
|
Another study of how to give fluorouracil?
|
J Clin Oncol
|
2003
|
0.77
|
|
79
|
Is adjuvant therapy for stage II colon cancer worthwhile, and for whom?
|
Nat Clin Pract Gastroenterol Hepatol
|
2008
|
0.77
|
|
80
|
Frequency, characteristics, and correlates of pain in a pilot study of colorectal cancer survivors 1-10 years post-treatment.
|
Pain Med
|
2013
|
0.77
|
|
81
|
Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance.
|
Clin Colorectal Cancer
|
2013
|
0.76
|
|
82
|
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum.
|
Invest New Drugs
|
2004
|
0.76
|
|
83
|
Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.
|
Invest New Drugs
|
2008
|
0.75
|
|
84
|
Antitumor activity in metastatic disease does not predict efficacy in the adjuvant setting.
|
JAMA
|
2012
|
0.75
|
|
85
|
Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma.
|
Gastrointest Cancer Res
|
2012
|
0.75
|
|
86
|
Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
|
Nat Med
|
2017
|
0.75
|
|
87
|
Update: colorectal cancer guidelines.
|
J Natl Compr Canc Netw
|
2003
|
0.75
|
|
88
|
Management of metastatic colorectal cancer.
|
Oncology (Williston Park)
|
2014
|
0.75
|
|
89
|
Managing chemotherapy-induced diarrhea.
|
Clin Adv Hematol Oncol
|
2006
|
0.75
|
|
90
|
30-day-or-sooner readmissions of gastrointestinal medical oncology patients following cancer center inpatient service discharge: characteristics and preventability.
|
Hosp Pract (1995)
|
2014
|
0.75
|
|
91
|
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.
|
Cancer Invest
|
2009
|
0.75
|